SCHEMBL1254579

SCHEMBL1254579

Sc1c(Cl)[c]ccc1Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11562093 0.77
SCHEMBL60891 0.74
SCHEMBL180192 0.70
SCHEMBL5376851 0.70
SCHEMBL11244359 0.70
SCHEMBL407446 0.70
SCHEMBL539105 0.70
SCHEMBL18037093 0.70
SCHEMBL15064196 0.70
SCHEMBL2159908 0.68 IDO1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2116244-B1 Method of treating atherosclerosis, dyslipidemias and related conditions SCHERING CORP (US) 2012-08-08 EP disclosed
US-20110118292-A1 METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS CHENG KANG 2011-05-19 US disclosed
EP-2286816-A1 Method of treating atherosclerosis, dyslipidemias and related conditions MERCK SHARP & DOHME (I.A.) CORP. (US) 2011-02-23 EP disclosed
EP-1558614-B1 PYRIDOPYRROLIZINE AND PYRIDOINDOLIZINE DERIVATIVES MERCK FROSST CANADA LTD (CA) 2010-09-01 EP disclosed
US-20100076002-A1 Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions and Pharmaceutical Compositions CHENG KANG 2010-03-25 US disclosed
US-7618979-B2 Pyridopyrrolizine and pyridoindolizine derivatives MERCK FROSST CANADA LTD. (CA) 2009-11-17 US disclosed
EP-2116244-A1 Method of treating atherosclerosis, dyslipidemias and related conditions Merck & Co., Inc. (US) 2009-11-11 EP disclosed
US-20090233977-A1 Method of Treating Atherosclerosis, dyslipidemias and related conditions MERCK SHARP & DOHME CORP. 2009-09-17 US disclosed
EP-1809284-A4 NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK & CO INC (US) 2009-09-09 EP disclosed
EP-1874301-A4 NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK & CO INC (US) 2009-05-06 EP disclosed
WO-2006052555-A2 NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK & CO., INC. (US) 2006-05-18 WO disclosed
WO-2006052798-A2 METHOD OF TREATING PATHOLOGICAL BLUSHING MERCK & CO., INC. (US) 2006-05-18 WO disclosed
WO-2006026273-A2 METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS MERCK & CO., INC. (US) 2006-03-09 WO disclosed
EP-1624871-A1 METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS AND PHARMACEUTICAL COMPOSITIONS Merck &amp; Co., Inc. (a New Jersey corp.) (US) 2006-02-15 EP disclosed
US-20050272756-A1 Pyridopyrrolizine and pyridoindolizine derivatives MERCK CANADA INC. (CA) 2005-12-08 US disclosed
EP-1558614-A1 PYRIDOPYRROLIZINE AND PYRIDOINDOLIZINE DERIVATIVES Merck Frosst Canada &amp; Co. (CA) 2005-08-03 EP disclosed
WO-2004103370-A1 METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS AND PHARMACEUTICAL COMPOSITIONS MERCK & CO., INC. (US) 2004-12-02 WO disclosed
US-20040229844-A1 Method of treating atherosclerosis, dyslipidemias and related conditions CHENG KANG (US) 2004-11-18 US disclosed
WO-2004039807-A1 PYRIDOPYRROLIZINE AND PYRIDOINDOLIZINE DERIVATIVES MERCK FROSST CANADA & CO. (CA) 2004-05-13 WO disclosed
US-4350518-A Plant growth regulating substituted alkylammonium salts BASF AKTIENGESELLSCHAFT (DE) 1982-09-21 US disclosed